

Premier Biomedical Successfully Advances Cancer Research

Cancer Tumor Killed in a Test Tube by Removing Targeted Antigens

ST. PETERSBURG, Fla., Dec. 5, 2012 /PRNewswire/ -- [Premier Biomedical, Inc.](#) (OTC-BB: BIEI) today announced successful advances in its cancer-focused research. Researchers successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds necessary for the cancer's development. This was accomplished utilizing the Felder Doctrine™: "Physically remove the pathophysiologic basis of the disease."

Dr. Mitchell S. Felder, Chairman of Premier Biomedical, Inc.'s Scientific Advisory Board, stated: "At best, conventional methods, such as chemotherapy and many current marketed cancer-fighting drugs, can target only one single antigen, thus allowing another antigen to survive the treatment and enabling the cancer to progress. Plus, these blockers or inhibitors often come with dangerous side effects to the patient. Premier Biomedical aims for far greater efficacy through mixing and matching multiple cancer target antigens simultaneously. We actually remove the pathophysiologic basis of the disease – targeting the exact cause of the disease and eliminating it – without dangerous side effects."

Specifically, the researchers removed a specified cancer-related Interleukin from a heterogeneous mixture at a picogram (trillionth of a gram) level of accuracy. This may open the door to a methodology for eradicating cancer tissue without the use of any other medications and/or procedures that are often accompanied by related side effects. Further testing has resulted in the successful removal of additional critical cancer-related antigens which are important in the development, growth, and metastasis of cancer tissue. Leukemia and lymphoma cancers were the focus of these recent successes.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "**BIEI**." www.premierbiomedicalinc.com

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact

Premier Biomedical, Inc.
William A. Hartman, CEO
(814) 786-8849
info@premierbiomedicalinc.com

SOURCE Premier Biomedical, Inc.